Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.64 |
| ▸ | PAM | P19021 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PRKCA | P17252 | 1/20 | 0.49 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8084720 | 1.00 | DGKA (0.64) | DGKAPAMMAPTTSHRLMNA | |
| SCHEMBL6536458 | 1.00 | DGKA (0.64) | DGKAPAMMAPTTSHRLMNA | |
| SCHEMBL3161151 | 1.00 | DGKA (0.64) | DGKAPAMMAPTTSHRLMNA | |
| SCHEMBL4624636 | 1.00 | DGKA (0.64) | DGKAPAMMAPTTSHRLMNA | |
| SCHEMBL13073330 | 1.00 | DGKA (0.64) | DGKAPAMMAPTTSHRLMNA | |
| SCHEMBL5709908 | 1.00 | DGKA (0.64) | DGKAPAMMAPTTSHRLMNA | |
| Ammonia Solution, Strong SCHEMBL6749467 | 0.98 | DGKA (0.62) | DGKAPAMMAPTTSHRLMNA | |
| SCHEMBL245738 | 0.98 | DGKA (0.61) | DGKAPAMMAPTTSHRLMNA | |
| Ethylene Glycol SCHEMBL9815228 | 0.94 | DGKA (0.58) | DGKAPAMMAPTTSHRLMNA | |
| Ethylene Glycol SCHEMBL9390653 | 0.94 | DGKA (0.58) | DGKAPAMMAPTTSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239790-A1 | NOVEL RECOMBINANT PROTEINS WITH N-TERMINAL FREE THIOL | POOL CHADLER | 2009-09-24 | — | — | US | disclosed |
| EP-1641481-A4 | FORMATION OF NOVEL ERYTHROPOIETIN CONJUGATES USING TRANSGLUTAMINASE | CENTOCOR INC (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1699920-A4 | NOVEL RECOMBINANT PROTEINS WITH N-TERMINAL FREE THIOL | CENTOCOR INC (US) | 2008-05-28 | — | — | EP | disclosed |
| EP-1699920-A2 | NOVEL RECOMBINANT PROTEINS WITH N-TERMINAL FREE THIOL | CENTOCOR, INC. (US) | 2006-09-13 | — | — | EP | disclosed |
| US-7074755-B2 | Erythropoietin conjugate compounds with extended half-lives | CENTOCOR, INC. (US) | 2006-07-11 | — | — | US | disclosed |
| US-20060116322-A1 | Formation of novel erythropoietin conjugates using transglutaminase | CENTOCOR, INC. | 2006-06-01 | — | — | US | disclosed |
| EP-1641481-A2 | FORMATION OF NOVEL ERYTHROPOIETIN CONJUGATES USING TRANSGLUTAMINASE | CENTOCOR, INC. (US) | 2006-04-05 | — | — | EP | disclosed |
| US-6995245-B2 | Formation of novel erythropoietin conjugates using transglutaminase | CENTOCOR, INC. (US) | 2006-02-07 | — | — | US | disclosed |
| EP-1144452-B1 | MODIFIED ANTIBODIES AND ANTIBODY FRAGMENTS WITH INCREASED DURATION OF ACTIVITY | CENTOCOR INC (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050170457-A1 | Novel recombinant proteins with N-terminal free thiol | CENTOCOR, INC. | 2005-08-04 | — | — | US | disclosed |
| WO-2005065239-A2 | NOVEL RECOMBINANT PROTEINS WITH N-TERMINAL FREE THIOL | CENTOCOR, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20040266690-A1 | Formation of novel erythropoietin conjugates using transglutaminase | CENTOCOR INC. | 2004-12-30 | — | — | US | disclosed |
| WO-2004108667-A2 | FORMATION OF NOVEL ERYTHROPOIETIN CONJUGATES USING TRANSGLUTAMINASE | CENTOCOR, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004106373-A1 | ERYTHROPOIETIN CONJUGATE COMPOUNDS WITH EXTENDED HALF-LIVES | CENTOCOR, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040229318-A1 | Erythropoietin conjugate compounds with extended half-lives | CENTOCOR, INC. | 2004-11-18 | — | — | US | disclosed |
| WO-2000026256-A9 | MODIFIED ANTIBODIES AND ANTIBODY FRAGMENTS WITH INCREASED DURATION OF ACTIVITY | CENTOCOR INC (US) | 2002-08-22 | — | — | WO | disclosed |
| EP-1144452-A3 | MODIFIED ANTIBODIES AND ANTIBODY FRAGMENTS WITH INCREASED DURATION OF ACTIVITY | CENTOCOR, INC. (US) | 2002-03-13 | — | — | EP | disclosed |
| EP-1144452-A2 | MODIFIED ANTIBODIES AND ANTIBODY FRAGMENTS WITH INCREASED DURATION OF ACTIVITY | CENTOCOR, INC. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000026256-A2 | MODIFIED ANTIBODIES AND ANTIBODY FRAGMENTS WITH INCREASED DURATION OF ACTIVITY | CENTOCOR, INC. (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266690-A1 | Formation of novel erythropoietin conjugates using transglutaminase | EPOR, HBG2, TGM3 | DGKA 2634/4885PAM 127/4885MAPT 2868/4885 |
| US-20060116322-A1 | Formation of novel erythropoietin conjugates using transglutaminase | EPOR, HBG2, TGM3 | DGKA 2634/4885PAM 127/4885MAPT 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.